Even if s-HER-2, like other circulating tumor markers, has limited usefulness for diagnosis and/or screening of BC, the US Food and Drug Administration (FDA) introduced its serum levels measurement for monitoring trastuzumab treatment in BC patients with HER-2 positive tissue and serum expression [50]. Here, ERBB2 is linked to neoplasm.